| Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a … SW Syversen, GL Goll, KK Jørgensen, Ø Sandanger, J Sexton, IC Olsen, ... Jama 325 (17), 1744-1754, 2021 | 129 | 2021 |
| Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a … SW Syversen, KK Jørgensen, GL Goll, MK Brun, Ø Sandanger, ... Jama 326 (23), 2375-2384, 2021 | 122 | 2021 |
| EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases CLM Krieckaert, A van Tubergen, JE Gehin, B Hernández-Breijo, ... Annals of the rheumatic diseases 82 (1), 65-73, 2023 | 48 | 2023 |
| Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV … SW Syversen, GL Goll, KK Jørgensen, IC Olsen, Ø Sandanger, JE Gehin, ... Trials 21, 1-14, 2020 | 37 | 2020 |
| Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study JE Gehin, GL Goll, DJ Warren, SW Syversen, J Sexton, EK Strand, ... Arthritis Research & Therapy 21, 1-10, 2019 | 37 | 2019 |
| Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine JE Gehin, GL Goll, MK Brun, M Jani, N Bolstad, SW Syversen BioDrugs 36 (6), 731-748, 2022 | 23 | 2022 |
| Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial MK Brun, GL Goll, KK Jørgensen, J Sexton, JE Gehin, Ø Sandanger, ... Journal of internal medicine 292 (3), 477-491, 2022 | 23 | 2022 |
| Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider C Krieckaert, B Hernández-Breijo, JE Gehin, G le Mélédo, A Balsa, M Jani, ... RMD open 8 (2), e002216, 2022 | 18 | 2022 |
| Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort JE Gehin, RA Klaasen, ES Norli, DJ Warren, SW Syversen, GL Goll, ... Rheumatology International 41 (9), 1657-1665, 2021 | 15 | 2021 |
| Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR … JE Gehin, DJ Warren, SW Syversen, E Lie, J Sexton, L Loli, A Wierød, ... Scandinavian Journal of Rheumatology 50 (6), 445-454, 2021 | 11 | 2021 |
| Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug-antibodies. Results from the Danish … B Glintborg, T Kringelbach, E Høgdall, IJ Sørensen, DV Jensen, AG Loft, ... Scandinavian Journal of Rheumatology 45 (Supplement 128), 6, 2016 | 11 | 2016 |
| HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases MK Brun, KH Bjørlykke, MK Viken, GE Stenvik, RA Klaasen, JE Gehin, ... Journal of Internal Medicine 293 (5), 648-655, 2023 | 9 | 2023 |
| THU0123 non-medical switch from originator to biosimilar infliximab among patients with inflammatory rheumatic disease–impact on s-infliximab and antidrug-antibodies. Results … B Glintborg, T Kringelbach, E Høgdall, IJ Sørensen, DV Jensen, AG Loft, ... Annals of the Rheumatic Diseases 75 (Suppl 2), 224-224, 2016 | 7 | 2016 |
| Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases I Jyssum, JE Gehin, J Sexton, EK Kristianslund, Y Hu, DJ Warren, ... Rheumatology 63 (6), 1746-1755, 2024 | 5 | 2024 |
| Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a … JE Gehin, SW Syversen, DJ Warren, GL Goll, J Sexton, N Bolstad, ... RMD open 7 (3), e001985, 2021 | 5 | 2021 |
| BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors B Hernández-Breijo, V Navarro-Compán, C Plasencia-Rodríguez, ... Scientific Reports 11 (1), 11632, 2021 | 5 | 2021 |
| Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis A Martínez-Feito, C Plasencia-Rodríguez, M Novella-Navarro, JE Gehin, ... Clinical and Experimental Rheumatology 42, 999-1005, 2024 | 4 | 2024 |
| Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials MK Brun, JE Gehin, KH Bjørlykke, DJ Warren, RA Klaasen, J Sexton, ... The Lancet Rheumatology 6 (4), e226-e236, 2024 | 3 | 2024 |
| Therapeutic drug monitoring: a tool to optimize treatment of inflammatory joint diseases SW Syversen, JE Gehin, GL Goll, N Bolstad, EA Haavardsholm, ... Arthritis Rheumatol Preprint posted online November 20, 2023 | 3 | 2023 |
| OP0017 THERAPEUTIC DRUG MONITORING COMPARED TO STANDARD TREATMENT OF PATIENTS STARTING INFLIXIMAB THERAPY: RESULTS FROM A MULTICENTRE RANDOMISED TRIAL OF 400 PATIENTS SW Syversen, GL Goll, KK Jørgensen, Ø Sandanger, J Sexton, I Olsen, ... Annals of the Rheumatic Diseases 79 (Suppl 1), 12-12, 2020 | 3 | 2020 |
